Intuitive Surgical (NASDAQ:ISRG) beat Q1 2026 earnings estimates with $2.77 billion in revenue and raised its full-year da Vinci procedure growth outlook, even as competitive pressure in China and Japan tests the durability of its international growth thesis.

Key Highlights

  • Q1 2026 revenue grew 23% year-over-year to $2.77 billion, beating consensus estimates by 5.73%.
  • Adjusted EPS of $2.50 surpassed analyst forecasts of $2.10 by nearly 19%, up 38% from Q1 2025.
  • Full-year 2026 da Vinci procedure growth guidance raised to 13.5%-15.5% from 13%-15%.
  • Da Vinci 5 utilisation runs approximately 11% higher than its predecessor Xi platform.
  • Competitive pressure in China and Japan continues to weigh on the international growth trajectory.

Earnings Beat Masks a More Complicated Operational Picture

Intuitive Surgical (NASDAQ:ISRG) reported first-quarter 2026 results that comfortably exceeded market expectations, reinforcing the structural growth thesis underpinning the surgical robotics sector. Revenue reached $2.77 billion, a 23% increase year-over-year, while non-GAAP earnings per share of $2.50 surpassed the average analyst consensus of $2.10. The company simultaneously raised its full-year forecast for da Vinci procedure growth to 13.5%-15.5%, up from the 13%-15% range offered in January.

The headline numbers, however, sit alongside a more nuanced operational picture. Procedure growth in China and Japan lagged the corporate average. A cybersecurity incident resulted in unauthorised access to customer and employee data. The US Food and Drug Administration issued a warning in March related to the company's surgical stapler. And the competitive environment is intensifying, with Medtronic's Hugo system launching commercially in the United States in February and CMR Surgical beginning its US rollout of the Versius Plus platform in March.

What the results ultimately demonstrate is that Intuitive's installed base, ecosystem depth, and innovation cadence continue to provide meaningful insulation from near-term disruptions, even as structural challenges accumulate in key markets.

Procedure Volume and Platform Dynamics

Total procedures grew 17% in Q1, comprising 16% da Vinci growth to 847,000 and 39% Ion bronchoscopy growth to 43,000. US da Vinci procedure growth came in at 14%, led by general surgery, with cholecystectomy and appendectomy combined growing 31%, supported by a 31% increase in after-hours procedures. Outside the United States, da Vinci procedures grew 19%, with particular strength in India, Canada, the United Kingdom, Korea, and Taiwan.

The da Vinci 5 platform, now installed across approximately 1,500 systems and used by nearly 13,000 surgeons, is the primary utilisation driver. Systems on da Vinci 5 generate roughly 11% higher utilisation than the Xi platform, pushing overall US utilisation growth to 4% in the quarter. The platform also achieved contribution margins comparable with Xi during Q1, removing a layer of profitability drag as the newer system scales. The SP single-port system delivered 68% procedure growth, with the company's SP stapler used in approximately 40% of eligible cases following its broad US launch in the quarter.

Margin Expansion and Innovation-Led Revenue

Non-GAAP gross margin reached 67.8%, up from 66.4% a year earlier, reflecting product cost reductions, fixed overhead leverage, and a favourable mix shift toward higher-value platforms. Da Vinci instrument and accessories revenue per procedure rose to approximately $1,880 from $1,780 a year earlier.

Chief Financial Officer Jamie Samath described this as innovation-led revenue growth, a deliberate strategy of directing research and development capital toward differentiated products that support accretive pricing. Revenue growth of 23% against procedure growth of 17% quantifies that premium directly. Non-GAAP operating margin was 39%. Full-year gross margin guidance was revised upward to 67.5%-68.5% from 67%-68% previously, with tariff headwinds now estimated at 100 basis points, down from 120 basis points in January.

China, Japan, and the Limits of International Expansion

The international growth narrative carries an important qualification. Procedure growth in both China and Japan fell below the corporate average, and neither market is on a clear near-term recovery path.

In China, the environment reflects lower tender activity, rising domestic competition, and policy-driven pricing pressure. Discussions with provincial authorities regarding potential reimbursement frameworks for robotic procedures are ongoing, but resolution is not expected before 2027. Japan presents a different dynamic. Procedure growth improved sequentially but remained below historical levels following reduced system placements in 2025. The Japanese Ministry of Health, Labour and Welfare recently introduced incremental reimbursement for hospitals exceeding 200 qualifying robotic cases annually and granted reimbursement for seven additional procedures from June 2026. These are constructive steps, but the effect on procedure volumes will take time to materialise given the financial constraints of public hospitals.

These two markets represent a tangible drag on international growth that has otherwise been a structural pillar of the Intuitive thesis. International procedure share has grown from 25% of total da Vinci volume a decade ago to 38% today, underscoring both the opportunity and the complexity ahead.

Structural Positioning in a Contested Market

Intuitive's Q1 results reflect a business executing with discipline in a sector that is becoming more contested. The competitive advantage rests on an installed base of approximately 10,000 da Vinci systems globally, an ecosystem of training and services that creates meaningful switching costs, and an innovation pipeline that has consistently generated revenue growth in excess of procedure volume growth.

Chief Executive Officer Dave Rosa outlined a digital roadmap centred on da Vinci 5 data, combining surgical video, kinematic, and force feedback streams to enable AI-assisted anatomy identification, augmented dexterity, and eventually telesurgery. The company ended the quarter with $8 billion in cash after $1.1 billion in share repurchases, signalling confidence in the underlying earnings trajectory.

The risks are real. Competitive entrants are gaining clearances in core markets. Macroeconomic pressure is affecting hospital capital budgets in Europe. China's policy environment remains opaque. For institutional investors, the relevant question is whether the innovation premium embedded in the current valuation is sustainable as competition intensifies. The Q1 data suggests the foundation remains intact. Execution in structurally challenged markets will determine whether it holds.